# A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

> **NCT06351631** · PHASE3 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 400 (estimated)

## Conditions studied

- Thrombocythemia, Essential
- Primary Myelofibrosis
- Myelofibrosis
- Post-polycythemia Vera Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
- Polycythemia Vera

## Interventions

- **DRUG:** Bomedemstat

## Key facts

- **NCT ID:** NCT06351631
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-23
- **Primary completion:** 2034-12-04
- **Final completion:** 2034-12-04
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06351631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06351631, "A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06351631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*